|
Incidence & Risk Factors
Over 2,000 new cases of mesothelioma are diagnosed in the United States
each year. Mesothelioma occurs more often in men than in women and risk
increases with age, but this disease can appear in either men or women
at any age. See statistics for more details.
Working with asbestos is the major risk factor for mesothelioma. A history
of asbestos exposure at work is reported in the majority of cases. However,
mesothelioma has been reported in some individuals without any known exposure
to asbestos.
Asbestos
Asbestos is the name of a group of minerals that occur naturally as masses
of strong, flexible fibers that can be separated into thin threads and
woven. Asbestos has been widely used in many industrial products, including
cement, brake linings, roof shingles, flooring products, textiles, and
insulation. If tiny asbestos particles float in the air, especially during
the manufacturing process, they may be inhaled or swallowed, and can cause
serious health problems. In addition to mesothelioma, exposure to asbestos
increases the risk of lung cancer, asbestosis (a noncancerous, chronic
lung ailment), and other cancers, such as those of the larynx and kidney.
Since the early 1940s, millions of American workers have been exposed
to asbestos dust. An increased risk of developing mesothelioma was originally
found among shipyard workers, people who work in asbestos mines and mills,
producers of asbestos products, workers in the heating and construction
industries, and other trades people. Today, the U.S. Occupational Safety
and Health Administration (OSHA) sets limits for acceptable levels of
asbestos exposure in the workplace. People who work with asbestos wear
personal protective equipment to lower their risk of exposure.
There is evidence that family members and others living with asbestos
workers have an increased risk of developing mesothelioma, and possibly
other asbestos-related diseases. This risk may be the result of exposure
to asbestos dust brought home on the clothing and hair of asbestos workers.
Symptoms
Symptoms of mesothelioma may not appear until 30 to 50 years after exposure
to asbestos. Shortness of breath and pain in the chest due to an accumulation
of fluid in the pleura are often symptoms of pleural mesothelioma. Symptoms
of peritoneal mesothelioma include weight loss and abdominal pain and
swelling due to a buildup of fluid in the abdomen. Other symptoms of peritoneal
mesothelioma may include bowel obstruction, blood clotting abnormalities,
anemia, and fever. If the cancer has spread beyond the mesothelium to
other parts of the body, symptoms may include pain, trouble swallowing,
or swelling of the neck or face.
Diagnosis
Diagnosing mesothelioma is often difficult, because the symptoms are
similar to those of a number of other conditions. Diagnosis begins with
a review of the patient's medical history, including any history of asbestos
exposure. A complete physical examination may be performed, including
x-rays of the chest or abdomen and lung function tests. A CT (or CAT)
scan or an MRI may also be useful.
A biopsy confirms a diagnosis of mesothelioma. In a biopsy, a surgeon
or a medical oncologist removes a sample of tissue for examination under
a microscope by a pathologist. (See Pathology Diagnosis to learn why some
patients request a second opinion.)
Mesothelioma is described as localized if the cancer is found only on
the membrane surface where it originated. It is classified as advanced
if it has spread beyond the original membrane surface to other parts of
the body, such as the lymph nodes, lungs, chest wall, or abdominal organs.
Treatment
Treatment for mesothelioma depends on the location of the cancer, the
stage of the disease, and the patient's age and general health. Standard
treatment options include surgery, radiation therapy, and chemotherapy.
Sometimes, these treatments are combined. Standard treatment for all but
localized mesothelioma is generally not curative.1 (See survival rates
for median survival rates with different treatments.)
Surgery - Extrapleural pneumonectomy in selected patients with early
stage disease may improve recurrence-free survival, but its impact on
overall survival is unknown. Pleurectomy and decortication can provide
palliative relief from symptomatic effusions, discomfort caused by tumor
burden, and pain caused by invasive tumor. Operative mortality from pleurectomy/decortication
is <2%, while mortality from extrapleural pneumonectomy has ranged
from 6% to 30%.2
Radiation/Chemotherapy - The use of radiation therapy in pleural mesothelioma
has been shown to alleviate pain in the majority of patients treated;
however, the duration of symptom control is short-lived. Single-agent
and combination chemotherapy have been evaluated in single and combined
modality studies. The most studied agent is doxorubicin, which has produced
partial responses in approximately 15% to 20% of patients studied. Some
combination chemotherapy regimens have been reported to have higher response
rates in small phase II trials; however, the toxic effects reported are
also higher, and there is no evidence that combination regimens result
in longer survival or longer control of symptoms.3
Alimta - The only FDA approved chemotherapy for malignant pleural mesothelioma
(in combination with cisplatin) is pemetrexed (Alimta). In the key clinical
trial that led to its approval, Alimta was combined with another chemotherapy
drug (cisplatin) and compared with cisplatin alone. The patients who received
the two drugs (Alimta and cisplatin) had their cancers progress (grow/spread)
in 5.7 months (median). The patients who only received cisplatin had their
tumors progress in 3.9 months (median). The median survival for the patients
who received both drugs was 12.1 months versus 9.3 months for cisplatin
only.4
Treatment Results
The Cancer Monthly database currently has the results
(survival, side effects, etc.) for 42 recent therapies for mesothelioma
including immunotherapy, biological therapy, radiation, chemotherapy,
surgery, and alternative therapy.
Sign Up and See the Results Right Now
Unless otherwise indicated by an endnote, the above material was adapted
from National Cancer Institute Cancer Facts - Mesothelioma: Questions
and Answers 5/13/2002.
--------------------------------------------------------------------------------
1 National Cancer Institute Malignant Mesothelioma (PDQ®): Treatment;
Health Professional Version - Treatment Option Overview available here
on September 30, 2005.
2 Id.
3 Id.
4 Vogelzang NJ, et al., Phase III study of pemetrexed in combination
with cisplatin versus cisplatin alone in patients with malignant pleural
mesothelioma . J Clin Oncol. 2003 Jul 15;21(14):2636-44.
|